Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05468697 2026-01-23

MK-6482-024

Phase 1/2 Active not recruiting

60 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05030506 2025-12-18

MK-6482-010

Phase 1 Active not recruiting

45 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Phase 3 Active not recruiting

249 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05239728 2025-08-14

MK-6482-022

Phase 3 Active not recruiting

1,800 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04626518 2025-07-25

KEYMAKER-U03

Phase 1/2 Active not recruiting

370 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02974738 2025-07-10

MK-6482-001

Phase 1 Active not recruiting

120 enrolled

CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3 Active not recruiting

755 enrolled 28 charts 1 FDA

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04976634 2025-04-06

MK-6482-016

Phase 2 Active not recruiting

730 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

MK-3475-03A

MK-6482-024

MK-6482-010

MK-6482-022

KEYMAKER-U03

MK-6482-001

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

MK-6482-016